Trials / Completed
CompletedNCT01285453
Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors
A Safety, Tolerability Study of Intravenous ASA404 Administered in Combination With Docetaxel in Japanese Patients With Advanced or Recurrent Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the tolerability of combination therapy with ASA404 and docetaxel in Japanese patients with advanced or recurrent solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vadimezan |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2009-12-01
- First posted
- 2011-01-28
- Last updated
- 2020-12-09
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01285453. Inclusion in this directory is not an endorsement.